Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Ovarian Neoplasms

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 79 articles: HTML format Text format

Single Articles

March 2010
1. SANZ DJ , Acedo A, Infante M, Duran M, et al
   A High Proportion of DNA Variants of BRCA1 and BRCA2 Is Associated with Aberrant Splicing in Breast/Ovarian Cancer Patients.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
2. GOODE EL , Maurer MJ, Sellers TA, Phelan CM, et al
   Inherited Determinants of Ovarian Cancer Survival.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
3. ANNUNZIATA CM , Walker AJ, Minasian L, Yu M, et al
   Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. RASOOL N , Larochelle W, Zhong H, Ara G, et al
   Secretory Leukocyte Protease Inhibitor Antagonizes Paclitaxel in Ovarian Cancer Cells.
   Clin Cancer Res. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
5. VIVAS-MEJIA P , Benito JM, Fernandez A, Han HD, et al
   c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   November 2009
6. MADER EK , Maeyama Y, Lin Y, Butler GW, et al
   Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   July 2009
7. BLAIR BG , Larson CA, Safaei R, Howell SB, et al
   Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin.
   Clin Cancer Res. 2009;15:4312-21.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. BORDEN KL
   Tissue targeting in cancer: eIF4E's tale.
   Clin Cancer Res. 2009;15:4254-5.
   PubMed     Text format     Related articles    Abstract available
   
   
   June 2009
9. MATTHEWS K , Noker PE, Tian B, Grimes SD, et al
   Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer.
   Clin Cancer Res. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   May 2009
10. MANGALA LS , Zuzel V, Schmandt R, Leshane ES, et al
    Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. KO SY , Guo H, Barengo N, Naora H, et al
    Inhibition of Ovarian Cancer Growth by a Tumor-targeting Peptide That Binds Eukaryotic Translation Initiation Factor 4E.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
12. MELHEM A , Yamada SD, Fleming GF, Delgado B, et al
    Administration of Glucocorticoids to Ovarian Cancer Patients Is Associated with Expression of the Anti-apoptotic Genes SGK1 and MKP1/DUSP1 in Ovarian Tissues.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
13. ARMAIZ-PENA GN , Mangala LS, Spannuth WA, Lin YG, et al
    Estrous Cycle Modulates Ovarian Carcinoma Growth.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. LEVINA V , Nolen BM, Marrangoni AM, Cheng P, et al
    Role of Eotaxin-1 Signaling in Ovarian Cancer.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. LEE JW , Shahzad MM, Lin YG, Armaiz-Pena G, et al
    Surgical Stress Promotes Tumor Growth in Ovarian Carcinoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2009
16. KULKARNI AA , Kingsbury SR, Tudzarova S, Hong HK, et al
    Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
17. BERCHUCK A , Iversen ES, Luo J, Clarke JP, et al
    Microarray Analysis of Early Stage Serous Ovarian Cancers Shows Profiles Predictive of Favorable Outcome.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. TAN DS , Lambros MB, Rayter S, Natrajan R, et al
    PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. DUIKER EW , de Vries EG, Mahalingam D, Meersma GJ, et al
    Enhanced Antitumor Efficacy of a DR5-Specific TRAIL Variant over Recombinant Human TRAIL in a Bioluminescent Ovarian Cancer Xenograft Model.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
20. AOKI D , Oda Y, Hattori S, Taguchi K, et al
    Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma.
    Clin Cancer Res. 2009;15:1473-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
21. HAMELERS IH , Staffhorst RW, Voortman J, de Kruijff B, et al
    High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.
    Clin Cancer Res. 2009;15:1259-68.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. ETEMADMOGHADAM D , Defazio A, Beroukhim R, Mermel C, et al
    Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas.
    Clin Cancer Res. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
23. SONG Y , Wu J, Oyesanya RA, Lee Z, et al
    Sp-1 and c-Myc Mediate Lysophosphatidic Acid-Induced Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Cells via a Hypoxia-Inducible Factor-1-Independent Mechanism.
    Clin Cancer Res. 2009;15:492-501.
    PubMed     Text format     Related articles    Abstract available
    
    
    
24. VAN HOLSBEKE C , Van Calster B, Testa AC, Domali E, et al
    Prospective internal validation of mathematical models to predict malignancy in adnexal masses: results from the international ovarian tumor analysis study.
    Clin Cancer Res. 2009;15:684-91.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. JANDIAL DD , Farshchi-Heydari S, Larson CA, Elliott GI, et al
    Enhanced delivery of Cisplatin to intraperitoneal ovarian carcinomas mediated by the effects of bortezomib on the human copper transporter 1.
    Clin Cancer Res. 2009;15:553-60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. KATZ E , Skorecki K, Tzukerman M
    Niche-dependent tumorigenic capacity of malignant ovarian ascites-derived cancer cell subpopulations.
    Clin Cancer Res. 2009;15:70-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
27. MARCHINI S , Mariani P, Chiorino G, Marrazzo E, et al
    Analysis of gene expression in early-stage ovarian cancer.
    Clin Cancer Res. 2008;14:7850-60.
    PubMed     Text format     Related articles    Abstract available
    
    
    
28. MABUCHI S , Terai Y, Morishige K, Tanabe-Kimura A, et al
    Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model.
    Clin Cancer Res. 2008;14:7781-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
29. CALLAHAN MJ , Nagymanyoki Z, Bonome T, Johnson ME, et al
    Increased HLA-DMB Expression in the Tumor Epithelium Is Associated with Increased CTL Infiltration and Improved Prognosis in Advanced-Stage Serous Ovarian Cancer.
    Clin Cancer Res. 2008;14:7667-7673.
    PubMed     Text format     Related articles    Abstract available
    
    
    
30. BHATTACHARYA R , Kwon J, Ali B, Wang E, et al
    Role of hedgehog signaling in ovarian cancer.
    Clin Cancer Res. 2008;14:7659-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. WEBB TJ , Giuntoli RL 2nd, Rogers O, Schneck J, et al
    Ascites specific inhibition of CD1d-mediated activation of natural killer T cells.
    Clin Cancer Res. 2008;14:7652-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. WALSH CS , Ogawa S, Scoles DR, Miller CW, et al
    Genome-Wide Loss of Heterozygosity and Uniparental Disomy in BRCA1/2-Associated Ovarian Carcinomas.
    Clin Cancer Res. 2008;14:7645-7651.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
33. MAEHLE L , Apold J, Paulsen T, Hagen B, et al
    High Risk for Ovarian Cancer in a Prospective Series Is Restricted to BRCA1/2 Mutation Carriers.
    Clin Cancer Res. 2008;14:7569-7573.
    PubMed     Text format     Related articles    Abstract available
    
    
    
34. SCHULTHEIS AM , Lurje G, Rhodes KE, Zhang W, et al
    Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab.
    Clin Cancer Res. 2008;14:7554-63.
    PubMed     Text format     Related articles    Abstract available
    
    
    
35. BAZZARO M , Lin Z, Santillan A, Lee MK, et al
    Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor.
    Clin Cancer Res. 2008;14:7340-7347.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. BEARFOOT JL , Choong DY, Gorringe KL, Campbell IG, et al
    Genetic Analysis of Cancer-Implicated MicroRNA in Ovarian Cancer.
    Clin Cancer Res. 2008;14:7246-50.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. SCURR LL , Guminski AD, Chiew YE, Balleine RL, et al
    Ankyrin Repeat Domain 1, ANKRD1, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer.
    Clin Cancer Res. 2008;14:6924-32.
    PubMed     Text format     Related articles    Abstract available
    
    
    
38. PAL T , Permuth-Wey J, Kumar A, Sellers TA, et al
    Systematic Review and Meta-analysis of Ovarian Cancers: Estimation of Microsatellite-High Frequency and Characterization of Mismatch Repair Deficient Tumor Histology.
    Clin Cancer Res. 2008;14:6847-54.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. LUTGENDORF SK , Lamkin DM, Jennings NB, Arevalo JM, et al
    Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma.
    Clin Cancer Res. 2008;14:6839-46.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
40. COATES RJ , Kolor K, Stewart SL, Richardson LC, et al
    Diagnostic Markers for Ovarian Cancer Screening: Not Ready for Routine Clinical Use.
    Clin Cancer Res. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. GREENE MH , Feng Z, Gail MH
    The Importance of Test Positive Predictive Value in Ovarian Cancer Screening.
    Clin Cancer Res. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. MCINTOSH M , Anderson G, Drescher C, Hanash S, et al
    Ovarian Cancer Early Detection Claims Are Biased.
    Clin Cancer Res. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
43. HENSLEY ML , Larkin J, Fury M, Gerst S, et al
    A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
    Clin Cancer Res. 2008;14:6310-6.
    PubMed     Text format     Related articles    Abstract available
    
    
    September 2008
44. QUAYE L , Gayther SA, Ramus SJ, Di Cioccio RA, et al
    The effects of common genetic variants in oncogenes on ovarian cancer survival.
    Clin Cancer Res. 2008;14:5833-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
45. HENIC E , Borgfeldt C, Christensen IJ, Casslen B, et al
    Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.
    Clin Cancer Res. 2008;14:5785-93.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. RAMUS SJ , Elmasry K, Luo Z, Gammerman A, et al
    Predicting clinical outcome in patients diagnosed with synchronous ovarian and endometrial cancer.
    Clin Cancer Res. 2008;14:5840-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. DRAPKIN R , Clauss A, Skates S
    Urokinase-type plasminogen activator receptor: a beacon of malignancy?
    Clin Cancer Res. 2008;14:5643-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
48. JOHNATTY SE , Beesley J, Paul J, Fereday S, et al
    ABCB1 (MDR 1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy.
    Clin Cancer Res. 2008;14:5594-601.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. LIN YG , Immaneni A, Merritt WM, Mangala LS, et al
    Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth.
    Clin Cancer Res. 2008;14:5437-5446.
    PubMed     Text format     Related articles    Abstract available
    
    
    
50. GUPTA D , Venkatesh M, Wang H, Kim S, et al
    Expanding the roles for pregnane x receptor in cancer: proliferation and drug resistance in ovarian cancer.
    Clin Cancer Res. 2008;14:5332-40.
    PubMed     Text format     Related articles    Abstract available
    
    
    
51. DE CESARE M , Calcaterra C, Pratesi G, Gatti L, et al
    Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
    Clin Cancer Res. 2008;14:5512-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
52. TOTHILL RW , Tinker AV, George J, Brown R, et al
    Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Clin Cancer Res. 2008;14:5198-208.
    PubMed     Text format     Related articles    Abstract available
    
    
    
53. CHIANG CL , Ledermann JA, Aitkens E, Benjamin E, et al
    Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor.
    Clin Cancer Res. 2008;14:4898-907.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
54. DE NICOLO A , Tancredi M, Lombardi G, Flemma CC, et al
    A Novel Breast Cancer-Associated BRIP1 (FANCJ/BACH1) Germ-line Mutation Impairs Protein Stability and Function.
    Clin Cancer Res. 2008;14:4672-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
55. CHU QS , Cianfrocca ME, Goldstein LJ, Gale M, et al
    A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
    Clin Cancer Res. 2008;14:4484-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
56. GARDNER ER , Dahut WL, Scripture CD, Jones J, et al
    Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
    Clin Cancer Res. 2008;14:4200-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
57. TONE AA , Begley H, Sharma M, Murphy J, et al
    Gene expression profiles of luteal phase fallopian tube epithelium from BRCA mutation carriers resemble high-grade serous carcinoma.
    Clin Cancer Res. 2008;14:4067-78.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2008
58. SOEGAARD M , Kjaer SK, Cox M, Wozniak E, et al
    BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark.
    Clin Cancer Res. 2008;14:3761-7.
    PubMed     Text format     Related articles    Abstract available
    
    
    
59. BANZATO A , Bobisse S, Rondina M, Renier D, et al
    A Paclitaxel-Hyaluronan Bioconjugate Targeting Ovarian Cancer Affords a Potent In vivo Therapeutic Activity.
    Clin Cancer Res. 2008;14:3598-606.
    PubMed     Text format     Related articles    Abstract available
    
    
    
60. TSURUTA Y , Pereboeva L, Breidenbach M, Rein DT, et al
    A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Clin Cancer Res. 2008;14:3582-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
61. WOLOSZYNSKA-READ A , Mhawech-Fauceglia P, Yu J, Odunsi K, et al
    Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer.
    Clin Cancer Res. 2008;14:3283-90.
    PubMed     Text format     Related articles    Abstract available
    
    
    
62. WANG Y , Saad M, Pakunlu RI, Khandare JJ, et al
    Nonviral nanoscale-based delivery of antisense oligonucleotides targeted to hypoxia-inducible factor 1 alpha enhances the efficacy of chemotherapy in drug-resistant tumor.
    Clin Cancer Res. 2008;14:3607-16.
    PubMed     Text format     Related articles    Abstract available
    
    
    
63. HAN LY , Fletcher MS, Urbauer DL, Mueller P, et al
    HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma.
    Clin Cancer Res. 2008;14:3372-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
64. STEFFENSEN KD , Waldstrom M, Olsen DA, Corydon T, et al
    Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors.
    Clin Cancer Res. 2008;14:3278-82.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2008
65. ISHIBASHI M , Nakayama K, Yeasmin S, Katagiri A, et al
    A BTB/POZ Gene, NAC-1, a Tumor Recurrence-Associated Gene, as a Potential Target for Taxol Resistance in Ovarian Cancer.
    Clin Cancer Res. 2008;14:3149-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    
66. DUNCAN TJ , Al-Attar A, Rolland P, Scott IV, et al
    Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?
    Clin Cancer Res. 2008;14:3030-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
67. DEVALAPALLY H , Duan Z, Seiden MV, Amiji MM, et al
    Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles.
    Clin Cancer Res. 2008;14:3193-203.
    PubMed     Text format     Related articles    Abstract available
    
    
    
68. MILNE RL , Osorio A, Cajal TR, Vega A, et al
    The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain.
    Clin Cancer Res. 2008;14:2861-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
69. DIEFENBACH CS , Gnjatic S, Sabbatini P, Aghajanian C, et al
    Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission.
    Clin Cancer Res. 2008;14:2740-2748.
    PubMed     Text format     Related articles    Abstract available
    
    
    
70. NAM EJ , Yoon H, Kim SW, Kim H, et al
    MicroRNA Expression Profiles in Serous Ovarian Carcinoma.
    Clin Cancer Res. 2008;14:2690-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
71. SCHOLLER N , Lowe KA, Bergan LA, Kampani AV, et al
    Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.
    Clin Cancer Res. 2008;14:2647-55.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2008
72. EGORIN MJ
    Population pharmacokinetc/pharmacodynamic modeling of Paclitaxel and Carboplatin in ovarian cancer.
    Clin Cancer Res. 2008;14:2517.
    PubMed     Text format     Related articles   
    
    
    March 2008
73. MEZZANZANICA D , Fabbi M, Bagnoli M, Staurengo S, et al
    Subcellular Localization of Activated Leukocyte Cell Adhesion Molecule Is a Molecular Predictor of Survival in Ovarian Carcinoma Patients.
    Clin Cancer Res. 2008;14:1726-1733.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2008
74. WALSH MD , Cummings MC, Buchanan DD, Dambacher WM, et al
    Molecular, Pathologic, and Clinical Features of Early-Onset Endometrial Cancer: Identifying Presumptive Lynch Syndrome Patients.
    Clin Cancer Res. 2008;.
    PubMed     Text format     Related articles    Abstract available   Free Full Text
    
    
    
75. SONG H , Hogdall E, Ramus SJ, Dicioccio RA, et al
    Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.
    Clin Cancer Res. 2008;14:1090-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
76. VISINTIN I , Feng Z, Longton G, Ward DC, et al
    Diagnostic Markers for Early Detection of Ovarian Cancer.
    Clin Cancer Res. 2008;.
    PubMed     Text format     Related articles    Abstract available   Free Full Text
    
    
    
77. GAGNON A , Kim JH, Schorge JO, Ye B, et al
    Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients.
    Clin Cancer Res. 2008;14:764-771.
    PubMed     Text format     Related articles    Abstract available
    
    
    
78. HEFLER LA , Concin N, Hofstetter G, Marth C, et al
    Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer.
    Clin Cancer Res. 2008;14:710-4.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2007
79. YANG T , Wall EM, Milne K, Theiss P, et al
    CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15 Dependent Mechanism.
    Clin Cancer Res. 2007;13:7172-80.
    PubMed     Text format     Related articles    Abstract available
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: